Literature DB >> 2392214

Response fluctuations in Parkinson's disease.

R A Roos1, C B Vredevoogd, E A van der Velde.   

Abstract

We studied the influence of several factors on the occurrence of response fluctuations in 91 Parkinson's disease patients. These included the age at onset, the presenting symptom, the duration of illness, and the stage of the disease at the time of initiation of levodopa treatment as time-independent covariates, and the mean and last dosage of levodopa as time-dependent covariates. Taken separately, none of the factors was related to the occurrence of response fluctuations. We found no evidence to delay levodopa treatment to a later stage of the disease. In the analysis of the combined influence of the age at onset and the interval before levodopa treatment, we noted a tendency for response fluctuations to occur less frequently in those patients with age at onset of 60 years and over who had started levodopa treatment more than 2 years after the 1st symptom. Our analysis of the combination of time-dependent factors suggests that response fluctuations are a likely event in those patients in whom the course of the disease recently necessitated an increase in the dosage of levodopa.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2392214     DOI: 10.1212/wnl.40.9.1344

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

Review 1.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Parkinson's disease.

Authors:  C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

Review 3.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

4.  Parkinson's Disease: Initial Treatment with Levodopa or Dopamine Agonists.

Authors:  Stewart A. Factor
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

Review 5.  Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Authors:  Stanley Fahn
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

6.  Age-related decrease in responsiveness to L-DOPA is not due to changes in dopamine receptor mRNAs or G protein mRNAs.

Authors:  M Murata; Y Aihara; H Yamanouchi; S Yamada; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 7.  Clinical pharmacology of dopamine agonists in Parkinson's disease.

Authors:  K W Lange
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 4.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.